CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ — Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. “We look forward to working with the Drug Repurposing … Read More
CHARLOTTESVILLE, Virginia, September 2, 2015 /PRNewswire/ — Biovista Inc. is glad to announce the sponsoring of the winners of the 2015 BeHEARD science challenge, a global competition hosted by the Rare Genomics Institute that offers rare disease researchers, access to the latest life science innovations and technologies.
CHARLOTTESVILLE, Virginia, June 23, 2015 /PRNewswire/ — Biovista Inc. today announced the publication of data from research it carried out in collaboration with the FDA and Israeli HMO Clalit, focusing on the prediction of risk factors related to targeted diseases. The research, published in the American Diabetes Association journal Diabetes Care, identifies hypothyroidism as a … Read More
CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More
CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ — Biovista announced today that it has been awarded a prestigious research grant by Solve ME/CFS Initiative to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS). As part of its work, Biovista will share … Read More